The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro - evaluation towards understanding breast cancer cell bone metastasis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Du, William W ^a,c   Fang, Ling ^a,b   Yang, Weining ^a,c   Sheng, Wang ^a,b   Zhang, Yaou ^a,b   Seth, Arun ^a,b   Yang, Burton B ^a,b   Yee, Albert J ^a,c  

^a Canada   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c DEPARTMENT OF RADIATION ONCOLOGY   (Canada)

Author keywords

Apoptosis; Cell differentiation; G3 domain; Invasion; Metastasis; Versican

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 4 (3 CHLOROANILINO) 6,7 DIMETHOXYQUINAZOLINE; ALKALINE PHOSPHATASE; ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; CELL PROTEIN; EPIDERMAL GROWTH FACTOR RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PROTEIN GSK 3BETA; PROTEIN KINASE B; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA1; TRICIRIBINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VERSICAN; VERSICAN G3;

ANIMAL CELL; APOPTOSIS; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER CELL CULTURE; CANCER GROWTH; CANCER INVASION; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL VIABILITY; COLORIMETRY; CONTROLLED STUDY; COULTER COUNTER; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME LINKED IMMUNOSORBENT ASSAY; IN VITRO STUDY; INHIBITION KINETICS; MICROSCOPY; MIGRATION INHIBITION; MOUSE; NONHUMAN; OSTEOBLAST; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; SIGNAL TRANSDUCTION; STROMA CELL; STRUCTURE ANALYSIS;

AMINO ACID MOTIFS; ANIMALS; APOPTOSIS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CULTURE MEDIA, CONDITIONED; EPIDERMAL GROWTH FACTOR; FEMALE; GENE EXPRESSION; HUMANS; MICE; MODELS, BIOLOGICAL; NEOPLASM METASTASIS; OSTEOBLASTS; PROTEIN INTERACTION DOMAINS AND MOTIFS; VERSICANS;

EID: 84864498441     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-341     Document Type: Article

References (55)

1. Felding-Habermann B, O'Toole TE, Smith JW, Fransvea E, Ruggeri ZM, Ginsberg MH, Hughes PE, Pampori N, Shattil SJ, Saven A, et al. Integrin activation controls metastasis in human breast cancer. Proc Natl Acad Sci U S A 2001, 98(4):1853-1858. 10.1073/pnas.98.4.1853, 29346, 11172040.
2. Couzin J. Medicine. Tracing the steps of metastasis, cancer's menacing ballet. Science 2003, 299(5609):1002-1006. 10.1126/science.299.5609.1002, 12586919.
3. Valentiner U, Brooks SA, Schumacher U. In vivo xenograft models of breast cancer metastasis. Methods Mol Med 2006, 120:479-488.
4. Fidler IJ. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat Rev Cancer 2003, 3(6):453-458. 10.1038/nrc1098, 12778135.
5. Fidler IJ. Seed and soil revisited: contribution of the organ microenvironment to cancer metastasis. Surg Oncol Clin N Am 2001, 10(2):257-269. vii-viiii.
6. Mendoza M, Khanna C. Revisiting the seed and soil in cancer metastasis. Int J Biochem Cell Biol 2009, 41(7):1452-1462. 10.1016/j.biocel.2009.01.015, 19401145.
7. Yoneda T, Hiraga T. Crosstalk between cancer cells and bone microenvironment in bone metastasis. Biochem Biophys Res Commun 2005, 328(3):679-687. 10.1016/j.bbrc.2004.11.070, 15694401.
8. Siclari VA, Guise TA, Chirgwin JM. Molecular interactions between breast cancer cells and the bone microenvironment drive skeletal metastases. Cancer Metastasis Rev 2006, 25(4):621-633.
9. Guise TA, Mohammad KS, Clines G, Stebbins EG, Wong DH, Higgins LS, Vessella R, Corey E, Padalecki S, Suva L, et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 2006, 12(20 Pt 2):6213s-6216s.
10. Yamaguchi Y. Lecticans: organizers of the brain extracellular matrix. Cell Mol Life Sci 2000, 57(2):276-289. 10.1007/PL00000690, 10766023.
11. Theocharis AD. Versican in health and disease. Connect Tissue Res 2008, 49(3):230-234. 10.1080/03008200802147571, 18661349.
12. Yee AJ, Akens M, Yang BL, Finkelstein J, Zheng PS, Deng Z, Yang B. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res 2007, 9(4):R47. 10.1186/bcr1751, 2206723, 17662123.
13. Wu Y, Chen L, Cao L, Sheng W, Yang BB. Overexpression of the C-terminal PG-M/versican domain impairs growth of tumor cells by intervening in the interaction between epidermal growth factor receptor and beta1-integrin. J Cell Sci 2004, 117(Pt 11):2227-2237.
14. Zheng PS, Vais D, Lapierre D, Liang YY, Lee V, Yang BL, Yang BB. PG-M/versican binds to P-selectin glycoprotein ligand-1 and mediates leukocyte aggregation. J Cell Sci 2004, 117(Pt 24):5887-5895.
15. Xiang YY, Dong H, Wan Y, Li J, Yee A, Yang BB, Lu WY. Versican G3 domain regulates neurite growth and synaptic transmission of hippocampal neurons by activation of epidermal growth factor receptor. J Biol Chem 2006, 281(28):19358-19368. 10.1074/jbc.M512980200, 16648628.
16. Nara Y, Kato Y, Torii Y, Tsuji Y, Nakagaki S, Goto S, Isobe H, Nakashima N, Takeuchi J. Immunohistochemical localization of extracellular matrix components in human breast tumours with special reference to PG-M/versican. Histochem J 1997, 29(1):21-30. 10.1023/A:1026460700592, 9088942.
17. Ricciardelli C, Brooks JH, Suwiwat S, Sakko AJ, Mayne K, Raymond WA, Seshadri R, LeBaron RG, Horsfall DJ. Regulation of stromal versican expression by breast cancer cells and importance to relapse-free survival in patients with node-negative primary breast cancer. Clin Cancer Res 2002, 8(4):1054-1060.
18. Suwiwat S, Ricciardelli C, Tammi R, Tammi M, Auvinen P, Kosma VM, LeBaron RG, Raymond WA, Tilley WD, Horsfall DJ. Expression of extracellular matrix components versican, chondroitin sulfate, tenascin, and hyaluronan, and their association with disease outcome in node-negative breast cancer. Clin Cancer Res 2004, 10(7):2491-2498. 10.1158/1078-0432.CCR-03-0146, 15073129.
19. LaPierre DP, Lee DY, Li SZ, Xie YZ, Zhong L, Sheng W, Deng Z, Yang BB. The ability of versican to simultaneously cause apoptotic resistance and sensitivity. Cancer Res 2007, 67(10):4742-4750. 10.1158/0008-5472.CAN-06-3610, 17510402.
20. Sheng W, Wang G, La Pierre DP, Wen J, Deng Z, Wong CK, Lee DY, Yang BB. Versican mediates mesenchymal-epithelial transition. Mol Biol Cell 2006, 17(4):2009-2020. 10.1091/mbc.E05-10-0951, 1415306, 16452631.
21. Sheng W, Wang G, Wang Y, Liang J, Wen J, Zheng PS, Wu Y, Lee V, Slingerland J, Dumont D, et al. The roles of versican V1 and V2 isoforms in cell proliferation and apoptosis. Mol Biol Cell 2005, 16(3):1330-1340. 10.1091/mbc.E04-04-0295, 551496, 15635104.
22. Du WW, Yang BB, Shatseva TA, Yang BL, Deng Z, Shan SW, Lee DY, Seth A, Yee AJ. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One 2010, 5(11):e13828. 10.1371/journal.pone.0013828, 2974650, 21079779.
23. Du WW, Yang BB, Yang BL, Deng Z, Fang L, Shan SW, Jeyapalan Z, Zhang Y, Seth A, Yee AJ. Versican G3 Domain Modulates Breast Cancer Cell Apoptosis: a Mechanism for Breast Cancer Cell Response to Chemotherapy and EGFR Therapy. PLoS One 6(11):e26396.
24. Du WW, Seth A, Yang BB, Yee AJ. The role of versican in modulating breast cancer cell self-renewal.The 65 Annual Meeting of the Orthopaedic Research Society, 2012 Feb 4-7 2012, 182. San Franciso, California.
25. Lelekakis M, Moseley JM, Martin TJ, Hards D, Williams E, Ho P, Lowen D, Javni J, Miller FR, Slavin J, et al. A novel orthotopic model of breast cancer metastasis to bone. Clin Exp Metastasis 1999, 17(2):163-170. 10.1023/A:1006689719505, 10411109.
26. Tao K, Li J, Warner J, MacLeod K, Miller FR, Sahagian GG. Multiple lysosomal trafficking phenotypes in metastatic mouse mammary tumor cell lines. Int J Oncol 2001, 19(6):1333-1339.
27. Mi Z, Guo H, Wai PY, Gao C, Kuo PC. Integrin-linked kinase regulates osteopontin-dependent MMP-2 and uPA expression to convey metastatic function in murine mammary epithelial cancer cells. Carcinogenesis 2006, 27(6):1134-1145. 10.1093/carcin/bgi352, 16474180.
28. Zhang Y, Wu Y, Cao L, Lee V, Chen L, Lin Z, Kiani C, Adams ME, Yang BB. Versican modulates embryonic chondrocyte morphology via the epidermal growth factor-like motifs in G3. Exp Cell Res 2001, 263(1):33-42. 10.1006/excr.2000.5095, 11161703.
29. Cicek M, Oursler MJ. Breast cancer bone metastasis and current small therapeutics. Cancer Metastasis Rev 2006, 25(4):635-644.
30. Zheng Y, Zhou H, Fong-Yee C, Modzelewski JR, Seibel MJ, Dunstan CR. Bone resorption increases tumour growth in a mouse model of osteosclerotic breast cancer metastasis. Clin Exp Metastasis 2008, 25(5):559-567. 10.1007/s10585-008-9172-4, 18421566.
31. Mastro AM, Gay CV, Welch DR, Donahue HJ, Jewell J, Mercer R, DiGirolamo D, Chislock EM, Guttridge K. Breast cancer cells induce osteoblast apoptosis: a possible contributor to bone degradation. J Cell Biochem 2004, 91(2):265-276. 10.1002/jcb.10746, 14743387.
32. Fromigue O, Kheddoumi N, Lomri A, Marie PJ, Body JJ. Breast cancer cells release factors that induced apoptosis in human bone marrow stromal cells. J Bone Miner Res 2001, 16(9):1600-1610. 10.1359/jbmr.2001.16.9.1600, 11547830.
33. Mercer RR, Miyasaka C, Mastro AM. Metastatic breast cancer cells suppress osteoblast adhesion and differentiation. Clin Exp Metastasis 2004, 21(5):427-435. 10.1007/s10585-004-1867-6, 15672867.
34. Gorter A, Zijlmans HJ, van Gent H, Trimbos JB, Fleuren GJ, Jordanova ES. Versican expression is associated with tumor-infiltrating CD8-positive T cells and infiltration depth in cervical cancer. Mod Pathol 2010, 23(12)):1605-1615.
35. Kischel P, Waltregny D, Dumont B, Turtoi A, Greffe Y, Kirsch S, De Pauw E, Castronovo V. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int J Cancer 2010, 126(3):640-650. 10.1002/ijc.24812, 19662655.
36. Wu YJ, La Pierre DP, Wu J, Yee AJ, Yang BB. The interaction of versican with its binding partners. Cell Res 2005, 15(7):483-494. 10.1038/sj.cr.7290318, 16045811.
37. LeBaron RG, Zimmermann DR, Ruoslahti E. Hyaluronate binding properties of versican. J Biol Chem 1992, 267(14):10003-10010.
38. Yamagata M, Yamada KM, Yoneda M, Suzuki S, Kimata K. Chondroitin sulfate proteoglycan (PG-M-like proteoglycan) is involved in the binding of hyaluronic acid to cellular fibronectin. J Biol Chem 1986, 261(29):13526-13535.
39. Kawashima H, Hirose M, Hirose J, Nagakubo D, Plaas AH, Miyasaka M. Binding of a large chondroitin sulfate/dermatan sulfate proteoglycan, versican, to L-selectin, P-selectin, and CD44. J Biol Chem 2000, 275(45):35448-35456. 10.1074/jbc.M003387200, 10950950.
40. Wu Y, Chen L, Zheng PS, Yang BB. beta 1-Integrin-mediated glioma cell adhesion and free radical-induced apoptosis are regulated by binding to a C-terminal domain of PG-M/versican. J Biol Chem 2002, 277(14):12294-12301. 10.1074/jbc.M110748200, 11805102.
41. Rahmani M, Wong BW, Ang L, Cheung CC, Carthy JM, Walinski H, McManus BM. Versican: signaling to transcriptional control pathways. Can J Physiol Pharmacol 2006, 84(1):77-92. 10.1139/y05-154, 16845893.
42. Faccio R. Immune regulation of the tumor/bone vicious cycle. Ann N Y Acad Sci 2011, 1237(1):71-78. 10.1111/j.1749-6632.2011.06244.x, 22082368.
43. Patel SA, Dave MA, Murthy RG, Helmy KY, Rameshwar P. Metastatic breast cancer cells in the bone marrow microenvironment: novel insights into oncoprotection. Oncol Rev 2011, 5(2):93-102. 10.1007/s12156-010-0071-y, 3138628, 21776337.
44. Teicher BA. Malignant cells, directors of the malignant process: role of transforming growth factor-beta. Cancer Metastasis Rev 2001, 20(1-2):133-143.
45. Ruppender NS, Merkel AR, Martin TJ, Mundy GR, Sterling JA, Guelcher SA. Matrix rigidity induces osteolytic gene expression of metastatic breast cancer cells. PLoS One 2010, 5(11):e15451. 10.1371/journal.pone.0015451, 2981576, 21085597.
46. Kong FM, Anscher MS, Murase T, Abbott BD, Iglehart JD, Jirtle RL. Elevated plasma transforming growth factor-beta 1 levels in breast cancer patients decrease after surgical removal of the tumor. Ann Surg 1995, 222(2):155-162. 10.1097/00000658-199508000-00007, 1234773, 7543740.
47. Drabsch Y, ten Dijke P. TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 2011, 16(2):97-108. 10.1007/s10911-011-9217-1, 3095797, 21494783.
48. Zhang Y, Cao L, Kiani CG, Yang BL, Yang BB. The G3 domain of versican inhibits mesenchymal chondrogenesis via the epidermal growth factor-like motifs. J Biol Chem 1998, 273(49):33054-33063. 10.1074/jbc.273.49.33054, 9830060.
49. Tumber A, Morgan HM, Meikle MC, Hill PA. Human breast-cancer cells stimulate the fusion, migration and resorptive activity of osteoclasts in bone explants. Int J Cancer 2001, 91(5):665-672. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1100>3.0.CO;2-3, 11267975.
50. Idriss HT, Naismith JH. TNF alpha and the TNF receptor superfamily: structure-function relationship(s). Microsc Res Tech 2000, 50(3):184-195. 10.1002/1097-0029(20000801)50:3<184::AID-JEMT2>3.0.CO;2-H, 10891884.
51. Szlosarek PW, Balkwill FR. Tumour necrosis factor alpha: a potential target for the therapy of solid tumours. Lancet Oncol 2003, 4(9):565-573. 10.1016/S1470-2045(03)01196-3, 12965278.
52. Wu Y, Zhang Y, Cao L, Chen L, Lee V, Zheng PS, Kiani C, Adams ME, Ang LC, Paiwand F, et al. Identification of the motif in versican G3 domain that plays a dominant-negative effect on astrocytoma cell proliferation through inhibiting versican secretion and binding. J Biol Chem 2001, 276(17):14178-14186.
53. Previdi S, Maroni P, Matteucci E, Broggini M, Bendinelli P, Desiderio MA. Interaction between human-breast cancer metastasis and bone microenvironment through activated hepatocyte growth factor/Met and beta-catenin/Wnt pathways. Eur J Cancer 2010, 46(9):1679-1691. 10.1016/j.ejca.2010.02.036, 20350802.
54. Guelcher SA, Sterling JA. Contribution of Bone Tissue Modulus to Breast Cancer Metastasis to Bone. Cancer Microenviron 2011, 4(3):247-259. 10.1007/s12307-011-0078-3, 3234324, 21789687.
55. Welch DR. Microarrays bring new insights into understanding of breast cancer metastasis to bone. Breast Cancer Res 2004, 6(2):61-64. 400646, 14979907.